Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
TL Stanley, MN Feldpausch, J Oh, KL Branch, H Lee… - Jama, 2014 - jamanetwork.com
Importance Among patients infected with human immunodeficiency virus (HIV), visceral
adiposity is associated with metabolic dysregulation and ectopic fat accumulation.
Tesamorelin, a growth hormone–releasing hormone analog, specifically targets visceral fat
reduction but its effects on liver fat are unknown. Objective To investigate the effect of
tesamorelin on visceral and liver fat. Design, Setting, and Patients Double-blind,
randomized, placebo-controlled trial conducted among 50 antiretroviral-treated HIV-infected …
adiposity is associated with metabolic dysregulation and ectopic fat accumulation.
Tesamorelin, a growth hormone–releasing hormone analog, specifically targets visceral fat
reduction but its effects on liver fat are unknown. Objective To investigate the effect of
tesamorelin on visceral and liver fat. Design, Setting, and Patients Double-blind,
randomized, placebo-controlled trial conducted among 50 antiretroviral-treated HIV-infected …